Two biotechnology companies headquartered in Seattle are engaged in the industry race to develop a vaccine for cancer, a competition in which some competitors claim to be within a year of achieving the goal. Dendreon and Xcyte Therapies are among the biotech companies that believe a vaccine for cancer is reachable as early as next year.

Full Story:
The Seattle Times

Related Summaries